Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial

Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial

Abstract Background Cytotoxic chemotherapy combinations and targeted agents represent established treatment concepts in advanced pancreatic neuroendocrine tumors (PNETs). However, response rates, side effects and outcome data strongly vary among these therapeutic approaches. Head-to-head comparisons...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sebastian Krug, Thomas Kegel, Thomas M. Gress, Anja Rinke, Leonidas Apostolidis, Henning Jann, Alexander König, Dieter Hörsch, Jörg Schrader, Thomas J. Ettrich, Michael Richter, Jörg Steighardt, Patrick Michl
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
PanNET
PNET
Chemotherapy
Ramucirumab
DTIC
Neuroendocrine
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/19ea4eac44d448f1a68eca27024409f7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/19ea4eac44d448f1a68eca27024409f7

Ejemplares similares